Banks, Gas, and Grass: The States Act.

Prompted during our '2019 Look at the Year Ahead' podcast, Blue mused over the States Act. It reminded me of a couple of historical events which I think are revealing - in terms of impact of trade within a nation - and can give us a glimpse into what the Act could mean for the cannabis sector. First, we'll have to go back to 1864, where an Act of Congress was passed....originally called "H.R. 455", it's become known as 'Act of June 8, 1864'. A significant amount has been written on it and the conditions…

Continue Reading

Production Constipation from New Formats

As we look at Legal Supply vs Demand and it’s eventual equilibrium, I think it’s important to start thinking about Legal Supply a little differently.A good deal of Joe Retail is looking at 2019 and wondering if Legal Supply will finally match up with Demand. This is usually accompanied by comments that with new formats there will be greater consumer demand, as new consumers (who don’t want to combust) enter the market, and those using illicit market formats migrate to the legal market as formats are introduced.A lot of the new…

Continue Reading

Evergreen Cannabis ~ Vancouver’s first cannabis RETAILER

Mike Babins looks tired.  But in that tiredness there is an unmistakable look of satisfaction. Mike and his wife, Maria Petrucci, are the proud parents of Vancouver’s first legal cannabis RETAILER.  I slipped several times and called it a “dispensary” and Mike politely corrected me.   I started to feel bad for the multiple corrections until Maria got out the sound “Disp…” before correcting herself. Old habits die hard.  But it is because of some of those old habits that Evergreen is Vancouver’s first legal cannabis RETAILER. Mike was kind enough to…

Continue Reading

Inside the Ropes Podcast #17

Our final (regular) podcast of 2018! We cover some recent events in the sector, with moves by Altria, Novartis, as well as Tilray, Cronos, and the blast crater surrounding the organized short on Aphria......Health Canada's regulation of edibles, and more.... We'll have two more coming shortly, having a look back at 2018 - as well as looking forward to the year ahead. Happy New Year! On Soundcloud, and on iTunes.....

Continue Reading

Organigram Q4 F2018 Rundown – Aug 31, 2018

OK… you may have read my Bah Humbug comment on the Sports Bar last night about Q4’s and how I wished that company’s would lay out the Q4 versus just doing an Annual aggregation.  Here is why…   Organigram 9 mos YTD 12 mos F2018 Delta Reported via MDA 31-May-18 31-Aug-18 Q4 F2018 Q4 F2018 Sales $9,611 $11,936 $2,325 $3,205 Sales returns $489 $493 $4 $8 Net Sales $10,100 $12,429 $2,329 $3,213 Cost of Sales $4,009 $4,659 $650 $1,068 Indirect production costs $1,002 $1,289 $287 $287   $5,011 $5,948 $937 $1,355…

Continue Reading

The Rebuttal – What can we expect from Aphria Wednesday??

I think expectations should be tempered on the Aphria rebuttal.  Why? Whereas there are number of allegations that can likely be proven false with pictures, statements, financial reports… the more damning of the allegations are innuendo and not fact based.  They are statements meant to illicit opinions that the reader can believe, or choose not to believe, impacted the transactions.   So how should an investor look at the short thesis??    Keeping in mind the shorters goal is to make you sell, they may make a “Statement of Fact” that…

Continue Reading

Aphria1 and DoubleDiamond Tour November 4, 2018

On November 4, 2018 TheCannalysts toured Aphria Diamond and Aphria1. Other than touring Broken Coast Cannabis for the “Boots on the Ground” documentary, this was the first time that all three Cannalysts have done a tour together.  What follows is each of our perspectives on the tour. Mollytime: Unlike my compatriots, I haven’t toured a large-scale formal greenhouse before. I’ve been confined to the pristine shoals of immaculate control: indoor only. So, being introduced to how professional agriculture approaches growing and processing and packaging…..and the logistics of it all at scale….it…

Continue Reading

Aphria Q2 F2018 Rundown

Open up the Financial Statements and MDA and follow along. First partial Q of adult rec is on the books. Cannabis sales [net of excise] was $19.5 million while non-cannabis sales were $2.2 million.  The increase in cannabis sales was $6.8 million a 53% increase QoQ, while non-cannabis was $1.6 million up from $0.6 million and attributable to Argentine asset ABP for 2 of 3 months in Q. Cannabis Sales in KGs increased to 3,409 up from 1,778 or 70%.  Rec accounted for 1,946 kgs [57% of total] while Medical was…

Continue Reading

Tour of MPX facility – Las Vegas Nov 2018

After touring a fair number of Canadian production facilities, it is an odd thing to see a large metal cabinet market 'pesticides' anywhere near a grow. As is seeing large spray canisters right beside it. One of the novelties about the Canadian experience I guess - being limited to some 22 registered pesticides, there is a fair amount of apprehension around their presence and visibility in grow ops. Even if they're called 'Doktor Doom Formula 420'.  Lots of biological vectors used to be sure though, and there were several bug sellers at MJBizCon…

Continue Reading

MJBizCon 2018 Las Vegas – Wrap Up

More than 30,000 listed for attendance, with some 1,000 booths, and some 50 different sessions over three days, this was the largest show I've been to. And I saw a ton of things. Dispensary Visit I got shlepped to a dispensary one day - an investor pitch combined with a tour of the operations. It was busy in the store, and they pound out the poundage. Products are segregated by quality: low, medium, high - and prices are variable accordingly. I also peeled off to one on my own lonesome, to…

Continue Reading

Tilray Q3 F2018 Rundown

USD unless noted. Last Q we noted on the Rundown and on “Inside The Ropes” podcast that Tilray had very little Finished Goods Inventory of Flower $89k and Extracts $361k at the end of the last Q and net decrease in overall cannabis inventory [decreased $913k].  We surmised that this would lead to either constrained sales growth unless they bought from 3rd parties, and if they did buy from third parties… a hit to gross margin. We have also repeatedly noted that NOT ONE financial media company has brought this up.…

Continue Reading

Live from MJBizCon 2018 – Vegas

Well. There's big, and then there's this. I don't know the number of people here, but it's into the tens of thousands. And the price of admission keeps the circus folk out - the expense account set who blaze all day in front of the hall admiring each other's weed while 'networking'. That's not to say there isn't gear here, there is. And boy, does it stink. I can summarize MJBizCon in 4 words: Extraction, terpenes, vapes, and lighting. There is an alcohol/beer tilt: Health Canada would lose their shit over…

Continue Reading

Cronos Q3 F2018 Rundown

Open up the financials and MDA and follow along. Sales Cronos evidenced a $0.4 million or 11% in crease in sales to $3.8 million.  They have some new disclosure that wasn’t available last Q, so I cannot track down the exact location of increase but I believe it to be all oil related.  Oil now constitutes 29% of overall sales. International sales make up $0.6 million of sales or 15% of mix. Again, new disclosure so no comparative. Sale price per gram increased to $7.32 from $7.12 likely due to higher…

Continue Reading

Aurora Cannabis Q1 F2019 Rundown

Open the financial statements and MDA and follow along. I said this last rundown for ACB…. "As a generalization…. If you take two firms with negative Adj EBITDA and you combine them the first Q will never look pretty [See Canopy-Mettrum].  You might get sales boost and other improvements, but to squeeze out synergies takes more than the first Q.  You throw in a huge ramp of Selling expenses and G&A to Day 1 of rec… and these results shouldn’t be too shocking [Illumination series was a cost with future benefit…

Continue Reading

The Year of the Breeder

When I was at the Vancouver Lift Expo in early January 2018, one of the panelists in one of the sessions declared 2018 to be the: ‘Year of Ancillary’. Pretty much nailed it. It’s wasn't that producers were going to immediately stop being fashionable for investors. It meant that the businesses surrounding the entire cannabis complex will start beginning to really hop. Packaging manufacturers. Testing companies. Those that support the core of production and processing and distribution - but aren't it. Lifestyle publications and information sources and bong makers and nutrient companies and…

Continue Reading

On the Road Again

In the aftermath of ‎WeCann™2018, I find myself a little tired, but also fired up 'tween the ears. Over the last while, our crew (and poor Blue) has had to suffer listening to my musings about cannabis being 'disruptive'. Kinda like how Uber and AirBnB are in their respective space. Cannabis ain't a technology tho. It's just a plant, right? Yeah. I've a favorite line I repeat to anyone unlucky enough to have asked my opinion. That cannabis lies at the intersection of many, many commercial roads. Recreational. CPG. Pharma. Ancillary.…

Continue Reading

Molly’s Trading Post: Closed for Business

I'm not going to go forward with the Trading Post. Over WeCann™, I spoke with a raft of people. And I also learned that without knowledge, context, and experience: concepts can be easily misconstrued. There might be miscommunication/misunderstanding. Perhaps someone skips a part. Maybe only get halfway through, and want to go rather than read the manual. Happens all the time. In all these cases, the potential downside is greater than the potential upside for TheCannalysts professionally, and me personally. Because I don't want to see someone beach on the rocks.…

Continue Reading

Liberty Health Sciences Q2 F2019

Open up the fins and MDA and follow along... A few items I would like to note prior to diving into fins… GMP received in June 2018… this will be important if/when Hemp gets pushed through Farm bill. Those big box stores want GMP. Issued more shares to satisfy a USD 6.0 million bill for work done on the 360 complex by Thermo Energy Systems [Leamington co… I might add.] 4 dispensaries operating for the Q.. 3 more open in Q3 with 4 new leases signed. That gets to 11 vs…

Continue Reading

State Monopolies and The Investor

I’ve railed at various times about the creation of State Monopolies to distribute cannabis. I’ve experience with them in my professional life - notably power, and interacting within the booze regime in Alberta, where I’d acquired an importation license to import tequila and craft beer from the states. It seems right to put all of it in one place, and explain why these Zombies of the State are an anachronism in the 21st century: utterly vulgar for consumers, businesses, investors, and ultimately......the citizen. When the pure, naked, and bottomless greed of…

Continue Reading

Mollytime’s Trading Post

One of the most lasting things that has stuck with me since business school was from an entry level course on futures and options. The 'perfesser said on Day 1: “Only a idiot would trade on technicals, and only a fool would ignore them”. That set up the first of many lessons I got over the next 20 years that would shape my views around trade. And one of the first things that got beat into me the first time I got near a trade floor was: If you don’t know…

Continue Reading

Aurora Cannabis Q4 F2018 Rundown

Open up the fins and the MDA and follow along.First off.. BIG thanks t Glen their CFO for having the courtesy to provide QoQ narrative on OPEX versus YoY comparisons. You have heard me grumble on how useless YoY comparisons are in a fast growing industry like this, so to provide colour is appreciated. Also… they let TheCannalysts ask a couple of Q’s. How about that!So let’s dig in…As a generalization…. If you take two firms with negative Adj EBITDA and you combine them the first Q will never look pretty…

Continue Reading

Cannabis: From Dumb Plants to Stable Cultivars

Almost a year ago I wrote “Cannabis: The Dumb Plant”, which was a simplistic look at why cannabis is different from conventional crops we know and love. In this article I’d like to delve a little deeper into what gives rise to variation within cannabis and how we can breed consistency into the phenotypes we desire.First off, what is a cultivar? A cultivar is a conserved set of traits within a species. Broccoli is a cultivar ofBrassica oleracea, if I plant 100 Brassica oleracea seeds from the broccoli variety, all of…

Continue Reading

Aphria Q1 F19 Aug 31, 2018 Rundown

I do want to add a comment before we get going….  Aphria always had an industry leading MDA in my opinion.  They stepped up their game considerably [as did ACB last Q].  They increased disclosure of Gain on Bios, FVI, QoQ impacts on cost per gram, and their detail on construction cost overruns and plant destruction were [to me] the type of disclosure the industry should strive towards.  They could always make me more happy by: providing kg’s harvested, sold and held in inventory like CGC or providing QoQ expense commentary…

Continue Reading

WeCann™ Conference

The Canadian Cannabis landscape is evolving at a tremendously fast pace. On October 17, 2018, Canada will become the first major industrial nation to legalize adult use cannabis. The formats to be offered on Day 1 provide a mere glimpse of where this industry is going, and the opportunity it presents. The Windsor-Essex region is on the trajectory to become Canada’s cannabis production capital. Accordingly, on November 6, 2018, TheCannalysts and Grant Thornton LLP present the WE Cann™ Conference, which profiles the present and future regional economic impact of the cannabis industry.…

Continue Reading

CannTrust Q3 F2018 Rundown

Well ain’t you a pleasure to review!! Positive EBITDA, FG inv growth, strong sales growth, Nice Production to Sales delta.  Rogers and Ravensdale will be finding work pretty quickly given these results. Open up the Fins and MDA and follow along. Sales An increase of 39% to $12.6 million [comparable to Tilray!!] Grams sold of flower dropped 14% QoQ but price per gram went up 16% to $8.77 = $3.5 million Extract went up to a new record of 699 kgs up 17% with price dropping less than 1% to $8.89…

Continue Reading

Tilray Q2 F2018 Rundown

Open up the fins and MDA and follow along.As this is my first Tilray rundown I trust the Community will be easy on me as I learn more about them. Usually it takes a few rundowns to settle in.SalesTilray increased sales to USD 9.7 million [C$ 12.8] a 25% increase QoQ. This was on 1514 KGs [1299 kgs last q] at a price per gram of C$8.38 vs C$7.55 last Q. A greater mix of higher value extracts – 46% up from 40% - is the reason. Cdn sales were up…

Continue Reading

Canopy Growth Q2 F2019 Rundown

After doing TRST last night, this is a sober reminder of the fact that this industry has a looong way to go.   To be fair to ACB, where I inserted a similar narrative for those that do not read the entire post,.… I will also talk about Net Operating Profit versus Net Income here.   CGC lost $330 million Net Income for the Q, with IFRS voodoo removed it was negative $290 million. Their Net Operating Income with IFRS voodoo backed out was negative $174 million. Net Operating Profit is…

Continue Reading

HEXO Facility Tour

by CytochromeP4 HEXO is Quebec’s largest licenced producer and the first Canadian licenced producer to offer active dried cannabis power and sublingual cannabis oil. Their Gatineau facility is projected to reach its full 108,000 kg of annual production, with a 1 million square foot greenhouse expansion by the end of 2018. The first crop expected to be harvested before Ontario brick & mortar opens their doors in the Spring of 2019. The current facility is comprised of the original greenhouse retrofitted for cannabis and new, purpose-built greenhouses divided into several sections.…

Continue Reading

CannTrust Q2 F2018 Rundown

Open up the fins and the MDA and follow along. TRST evidenced a 15% increase in QoQ revenue of $1.2 million. This on the backs of only an 8% increase in KGs sold, therefore… better pricing. Revenue per gram sold was $8.52 vs $7.98 last Q, an increase of 7%. Flower sales in absolute $ terms increased 11% at $7.59 a gram versus $7.27 last q. Oil sales in absolute $’s increased 20% at $8.95/gram equiv versus $7.89 last Q. Oil is now 59% of sales, an increase on mix of…

Continue Reading

Aphria Q4 F2018 Rundown

Open up the fin statements and the MDA to follow along.Sales:A pretty strong sales increase of 17% or $1.8 m to $12 million QoQ. This was despite an 8% drop in KG sold QoQ.Plus:+BCC for full Q versus 1 month… BCC now accounts for 484 KGs or 37% of sales by weight.+BCC averages over $10/.gram which increased Retail per gram to $9.25/gram from $8.30 an 11% improvement+Existing patients was a record 798 kgs a 49% improvement from last Q and above the 695 kgs record in Q2.Minus - headwinds-Onboarding dropped substantially…

Continue Reading

DHydra Technologies

DHydra Technologies drying machine, manufactured by AdvanTech, uses microwaves and a vacuum to pull the moisture out of cannabis. The same technology is currently used by some to dry fruits and vegetables. During the drying process low boiling point terpenes are also removed with water, but are recaptured.Their machine can dry 150 lb/hour of trim or whole flower. They’re leased to LP’s, starting with a small unit to test, then switching to a larger unit. Since it’s leased all maintenance is covered with trays being the only part that needs regular…

Continue Reading

Cronos Q2 F2018 Rundown

With Cronos changing their accounting presentation to what is becoming industry standard, I thought I’d do a light rundown.Sales increased 15% QoQ to their highest level yet of $3.4 million. This increase was off a drop in KGs sold to 477 kgs from 501 kgs [they have had a change in format of reporting this. I believe it to be correct]. This increase in sales off of lower kgs was a function of an increase in the overall price per gram QoQ to $7.12 from $5.88/gram, likely reflecting a reduction in…

Continue Reading

Liberty Health Sciences Q1 F2019 Rundown

I was going to put this in the Sports Bar... but figured I'd give it her own post given the subs interest.Open up the financials and MDA and follow along…Sales for the Q was $1.1 million up 164% QoQ or $709k. This is largely attributable to sizeable patient capture due to having 4 dispensaries running during the Q rather than one dispensary on the previous Q. Patients were 4,566 versus 1,999 last Q a 228% increase.Price per gram dropped from $19.99/gram to $15.99 gram.Gross Margin before IFRS voodoo [COGS and Dep…

Continue Reading

Organigram Q3 F2018 Rundown

Open up the financials and MDA and let’s take a look.SalesOgi experienced a 15% QoQ increase in Sales to $3.7 million or approximately $0.5 million. This increase results from a 28% increase in flower sales and 39% increase in oil sales. As the sales increase is less than those individual weight increases it means they are selling more weight at less revenue per unit.Some new disclosure: Once they report this for a few more Q’s Ill have a trend line.Sales are split $1,636 flower to patients, $1,363 oil to patients, and…

Continue Reading

Canopy Growth Q1 F2019 Rundown

Open up the fins and MDA and follow along. Before I dive in… congrats to Canopy and their shareholders. The news today was like several hole in ones in a row. I haven’t had time to dig all the way into the costs of the deal. But, damn… credit where credit is due Sales I am hoping CGC starts providing tables and a bridge on where revenue increases are coming from so I can check my spread against their data versus in the future. At $8.94/gram (a 6% QoQ increase) with…

Continue Reading

MedReleaf Q4 F2018 Rundown

This could be the final Leaf Rundown by yours truly if Acb completes the acquisition. So open up the Fin Stmts and MDA and let’s get to it! There is not a lot of narrative that is helpful in MDA explaining QoQ changes [pet peeve]. Sales increase QoQ of 6% and YoY of 8%. The VAC Meteor Strike has impacted Leaf for quite some time, and anyone looking at year over year will notice a substantial deterioration in YoY. Sales: The Sales increase of 6% QoQ was on the back of…

Continue Reading

Organigram Production Facility Tour – May 2018

Indoor growing offers 100% control over environment. Humidity, temperature, CO2 levels, air flow, lighting periods….everything. Cost structures are typically higher than other types of grows….expected to be offset by enhanced yield and quality. Organigram’s production facilities are located within an industrial area in Moncton. The buildings are low key and nondescript. Access to and security of the location is consistent with permitting under the ACMPR regime. All areas require keycard access, and entry/exit data is captured. Security is a large component A visual overview of the site - with expansion plans…

Continue Reading

Aurora Cannabis Q3 F2018 Rundown

Ok… pull up the financial statements and the MDA to follow along.Sales increased $4,400 to $16,100 or 38%$1,072 for Cannabis Sales to a total of $10,813 an 11% increase QoQ$554 Cdn Cannabis up 9% +$670 oil up 44% -$152 European Cannabis Sales down 6% [quite surprised that this dropped given new sales to Italy. I have heard rumours of German product not clearing customs, this net decrease might be an manifestation of that]$2,979 Construction Revenue [Larssen] – New revenue Category +$349 Service Revenue to a total of $2,308 an 18% QoQ…

Continue Reading

Organigram Q2 F2018 Rundown

OGI evidenced a 20% increase in sales or $532k QoQ [net sales including unused sales credit increased $1 million and 37%] driven largely by strong oil sales up 32% by volume and flower up 22% by weight. Oil sales by volume is at a record 552k ML, and flower of 238 kg has not yet reached the peak reached in Q ended Nov/2016 of 260 kg. As both the volume and weight increases are in excess of the Sales increase of 20% then price per volume and/or weight decreased. No revenue…

Continue Reading

Canopy Growth Q4 F2018 Rundown

Ok… time to pull out the financial statements and MDA and follow along. For the Q ended March 31, 2018 CGC evidenced $1.1 million (5.1%) increase in sales over Q3F18. Sales of product of $21,311 [$8.43/gram times grams sold versus total sales of $22.8 million] for Q4 represented an increase from Q3 of $19,339 or close to $2 million a 10% increase. Product sales increase was driven by Germany increase of $1.4 million to $2.3 million, with the balance being increase in Cdn product sales of $619k or only 3% QoQ…

Continue Reading

CannTrust Q1 F2018 Rundown

Open up the financial statements and MDA to follow along.TRST evidenced a 12% increase in sales for the Q, and there were a number of moving parts to this. They did drop in a new Note (#19) with a clean break out of $ sales. Problem is I do not have that note for last Q, so there is a gap in my Oil Sales by $ amount QoQ.Bud sales $3.0 million. Bud weight went up 40% while bud $ went up 35%. As a result Revenue per gram went down…

Continue Reading

Tweed Niagara Tour – April 2018

TheCannalysts attended a media day at Tweed Niagara, and joined in a tour of the grow space. Our host guide stated the facility currently has 350k ft2 in use, with plans to expand to a full 1MM ft2 over the next several months. After each grow, a full clean of the greenhouse is performed. There’s currently plastic sheeting over concrete that’s replaced during this turnover. Plants are currently segregated by stage of generative times, which spans 7-10 weeks depending on the cultivar. We queried whether different nutrients were used by cultivar…

Continue Reading

Cronos Group – Peace Natural facility tour – April 2018

At the start of the tour Mike told us you couldn’t use traditional production metrics to evaluate Peace Naturals. Those words hold true with writing a summary of the tour. The number of different things going on across the facility are reminiscent of agricultural R&D more than a typical LP. The basic layout of the facility consists of several separate indoor grow facilities, a small greenhouse and an almost complete 286,000 sq foot indoor grow building. The first plants expect to be growing in the new building by June/July. First stop…

Continue Reading

CannTrust Q4 F2017 Rundown

Open up the financials and MDA to follow along.   TRST recorded sales of $7.0 million for a 14% QoQ increase. Grams of flower sales increased 5% but were offset by a decline in price per gram to $8.14 from $8.81 sequentially, resulting in a 2.6% decrease in dollar sales.  Oil sales increased 24% in dollar sales with sales by ML growing at a like rate. Average revenue per ML decreased slightly from $2.04 to $1.97 but revenue per gram equivalent of Oil went up to $9.34/gram equiv from $9.27/gram equiv.   So…

Continue Reading

Aurora Cannabis Q2 F2018 Rundown

I don’t know how many of you folks actually spread quarterly financial statements. I do both the income statement and balance sheet, and then make a bunch of dives into the notes and the MDA to round out numbers with data I find interesting and pertinent to the analysis. And when it comes to the income statement, I do what is called “common sizing”. This is where I take all the expense items and measure it as a percentage in sales. By doing this the trends pop out more. Highly recommend…

Continue Reading

Organigram Q1 F2018 Rundown

Given how much I liked the OGI disclosure in their MDA, I decided to do my first rundown on them. Sales finally exceeded the previous record quarter [Q2-17 of $2.2 million] with $2.7 million, up 25% from the last Q. The sales increase was largely a result of a very impressive growth in Oil sales up 134% QoQ to 418,600 ml. Flower sales had a small bump of 4% to 195,075 grams, which is well off the record Q2-17 of 260,291 grams. [I couldn’t find sales price per gram for flower…

Continue Reading

Canopy Growth Q3 F2018 Rundown

Before I get into the rundown… I posted this last night in the "Big 5 Martini Bar".Feb 2018Maruoka thinks Canopy will generate EBITDA of $7.1-million on revenue of $116.0-million in fiscal 2018. He expects those numbers will improve to EBITDA of $139.9-million [28%] on a topline of $497.0-million the following year.Feb 2018Stanley thinks Canopy will generate EBITDA of negative $17.6-million on revenue of $87.1-million in fiscal 2018. He expects those numbers will improve to EBITDA of positive $19.5-million [7%] on a topline of $278.7-million the following year.I bring it up as…

Continue Reading

MedReleaf Q3 F2018 Rundown

Before I get to the rundown… MDA announces they have a Letter of Intent with SAQ for a minimum 8,000 kg a year for three years. And one of 6 LP’s to get a Letter of Intent. Happened in Feb/18… So where are the other LP announcements???Also, the conference call had technical difficulties and I hung up after a dead line occurred during Q’s.Sales increase QoQ to $11,850 a 15.6% increase. This was the first Q without any VAC changes from Nov/16 and May/17 muddying the trends. The bridge$880 in dry…

Continue Reading

Selective Comparison of the Cannabis Extraction Industry Part 3: Transdermal Cannabinoids

We’re spoiled for choice when it comes to our options for consuming cannabis. Smoking, eating, drinking, what variety we can have! What’s left? Patches? Injecting? Suppositories? No, no, too far. In this article I will talk about patches, including oral strips, that deliver cannabinoids to your blood stream through the external cell layers of your mouth and skin.Lifestyle Delivery System (LDS:CSE) sells an oral strip akin to a breath strip for delivery of cannabinoids. They claim you can feel the effects in 90 seconds or less. Comparable delivery time to smoking…

Continue Reading

Selective Comparison of the Cannabis Extraction Industry Part 2: Cannabis Beverages

In my last article on the Cannabis Extract Industry (CEI) I discussed various methods of extracting cannabis oil from the plant. In this article I will talk about how we process extracts to create cannabis beverages. I’m going to be focusing on Tinley Beverage Company (TNY:CSE), which produces cannabis/hemp drinks, and Isodiol (ISOL:CSE), who produce a product that can easily be turned into a hemp drink (I imagine they will expand to cannabis). I must note that I will not be giving any opinions on how these companies operate financially, thus I avoid…

Continue Reading

Canopy Growth Q2 F2018 Rundown

I originally posted this on r/weedstocks. As we have a BUNCH of new eyeballs on the sub, and I was messaged by a number of people asking if I do what I did yesterday on Aphria for other LP's [yes, TRST and LEAF are in the wiki]... I thought i'd re-post.I plan in doing ACB and Cronos after their next Q release. I spread their historics over Christmas [Elves were busy with Molly, so Blue ground these out on his own].BEFORE asking any Q's check and see if it was asked…

Continue Reading

MedReleaf Q2 F2018 Rundown

I imagine quite a few readers (new ones mostly) when they first hear u/mollytime rambling on about “regulatory meteor strikes” that will impact the cannabis sector in Canada ... likely roll their eyes and consider him a Chicken Little. Someone just raining on the parade. Well this review will remind a few readers (and be news to many folks who just got into cannabis investing in 2017) about a “regulatory meteor strike”. Welcome to my review of Medreleaf. You should probably start by reading thishttp://www.cbc.ca/news/politics/veterans-hehr-pot-policy-1.3861534 Actually you should also pull up…

Continue Reading

Canntrust Q3 F2017 Rundown

So I am looking for LPs that I want to hold long term. Aphria has been on a tear and is now over my PIII valuation [doesn’t mean I will not accumulate but I’d like a floor to establish as I still think they are $20 by early 2019 on low P/E of 20 .. + 53% by 2019], LHS puked on lack of Ohio license [but again I am looking for floor as I want to accumulate as I see it at $3.23 in 2020 .. +115% but by 2020]….So…

Continue Reading

Aphria Q2 F 2018 Rundown

Well I had a chance to look foolish with a 38% sales increase and $2.5 million EBITDA, and I look half foolish. Instead of doing an MDA rundown I am going to analyze this in my more traditional fashion… like when I write credit… Income Stmt, cash flow/EBITDA and then balance sheet items of note. I’ll draw from MDA for colour. They did beat the street EPS of 0.00 at 0.04. Sales: Up 39%... [not 38%... but I missed by 2% last Q so I am trending favourably] to $8.5 million.…

Continue Reading

Aphria MDA Q1 F2018

Q1 F2018 MDA Review… “Setting the table” [Best to have MDA to page flip with.] Recently I was chided by a CGC investor about “finally” recognizing the need for Operating Expenses (Opex) to sometimes lead sales. I referred to it as a “sales lag”. I do recognize the need, as I have built my own biz from scratch. And when you are in the early days there is a lot of hand to mouth and sleepless nights. But if luck, good fortune, understanding your market and your value proposal, and planning…

Continue Reading

Every Long in Cannabis should thank Canopy… but let’s look at the deal shall we

I wasn’t going to post this, as there is a party going on. But a discussion emerged in the daily thread and I thought a more thought out post would be better.Monday’s announcement was a great day for the cannabis sector. A long term hope that many of us investors held that big alcohol, tobacco, pharma and/or other would come play HAPPENED!! I think it was earlier than most thought, but it happened. The sector owes a big thanks to Canopy. The impact of this on other possible takeover targets is…

Continue Reading

How much extra capital will LP’s need to raise to float payment terms for Rec and Pharmacy?

Click edit button to change Now hanging hat at r/TheCannalysts As we approach day 1 of rec we also approach non cash payment terms for sales. LCBO isn't paying cash at delivery like current patients do. The provinces will be getting approximately 90 days from receipt of goods or invoice from LP's to pay for their mj. Private rec models for distribution certainly won't get 90 days to pay like a province owned would. Many dispensaries might be on cash terms. You may think, my LP doesn't have to worry about…

Continue Reading

When will the Canadian Commercial Banks start lending to the cannabis sector?

There is this general assumption that once rec happens the Canadian chartered banks are going to be falling all over themselves to lend to this sector.That could be one of the dominos that MAY need to fall. But there are bigger ones than day 1 of rec that need to be tipped.Commercial lending for Canadian banks is very homogeneous. They are subject to similar risk rating methodologies (Basel II when I was last inside), similar return requirements (RAROC: Risk Adjusted Return on Credit) they pretty well all use the same financial…

Continue Reading

Gain on Bios for the layman/laywoman: Lemonade Stand posts: CGC Q3 and Q4 F2017

Ok... these are two satirical posts trying to explain GoB. [To CGC Investors: These are historic looking numbers. I fully recognize that you are investing with forward looking view. So if you laughed at u/Monteviale ACB using shares to Buy Itself post, I’d hope this gives you a chuckle and some learnin’. ] Before you look down your nose at Stockhouse (where I originally posted these) I have heard from multiple sources that these stories have made the rounds of a number of I Banks. Q3 https://www.stockhouse.com/companies/bullboard/t.cgc/capital-gold-corporation?threadid=25856421 Q4 http://www.stockhouse.com/companies/bullboard/t.aph/aphria-inc?threadid=26416116 GoBlue

Continue Reading

Demystifying Gain on Biologicals

This is a post I did 5 months ago and was posted on r/weedstocks. Before you ask a Q see if it was already asked and answered. It is looong. https://www.reddit.com/r/weedstocks/comments/6k7qnt/demystifying_gain_on_biologicals_gob/ Given the live example CGC provided, and I get a ton of Q's on GoB, I thought I'd put up a post that may serve as a reference going forward. It is very difficult to analyze an LPs financial statements without understanding GoB. It is an International Financial Reporting Standard (IFRS) that impacts when profit from harvests is taken into…

Continue Reading

Cannabis: The Dumb Plant

I wrote this a while back to explain to someone why Canopy was growing different strains in their indoor facility than Aphria was growing in their greenhouses. When growing cannabis, water and light requirements must be kept within certain ranges at different stages in the grow process. Unlike crops we’ve cultivated for centuries, we haven’t selectively bred cannabis for stable growth traits required in industrial scale cultivation. Instead, we’ve bred the plant to produce the most THC/CBD with the greatest number of trichomes. You can picture the scenario as a human…

Continue Reading

Selective Comparison of the Cannabis Extract Industry Part 1: Extraction

When I look at and compare cannabis companies I always start by looking at their public documents. After some time trying to decipher how the companies operate, I inevitably get annoyed at the lack of detail in both their financial statements and on their websites. At this point I turn the scientific literature behind their products to glean some insight into the operations they don’t want to communicate with their shareholders. For some context, I started this analysis with the intention of comparing some of the companies on this listwith others…

Continue Reading

The Importance of Bearer Plants

What is marijuana? What is this plant? It gets us high and can be used to treat illnesses. What a wonderful plant! People have invested billions of dollars over the last few years into companies producing this wonderful plant. But what do we know about this plant? How does it grow? How do I make it grow better, or safeguard it from dying? Remember, it’s alive. We have invested billions of dollars into a complex and mysterious living biochemical factory and the surrounding infrastructure. Throughout my posts I hope to introduce…

Continue Reading

The Importance of Cannabis Oil

In my last article on Bearer Plants I talked about commercial propagation and financial reporting of the cannabis plant. In this article I will introduce cannabis oil in its many varieties. I will talk about what it is, how companies are using it in general terms, how they report cannabis oil in their financial statements and finally on the bioavailability of cannabis oil. This will be my last general science/financial reporting focused article before I start comparing individual companies and the products they produce. I need to write these articles first…

Continue Reading

CannTrust Niagara Greenhouse Tour – January 2018

I have been touring businesses for 30 plus years. I have been through several very advanced vehicle assembly facilities. Dr. Michael Ravensdale, VP of Operations and Quality, took Cyto and myself on a 3.5 hour tour. I have never had a 3.5 hour plant tour, EVER! And it flew by.Michael is a rare dude. PhD in Plant Pathology from University of Dundee who also spent a couple of years options trading. To have financial chops in the space he fills can only be seen as a benefit. TRST is about halfway…

Continue Reading

EBITDA… What it means in the long term for LPs and their investors…

Yesterday I was asked to repost this educational piece on EBITDA.I have provided a cross post below so folks can scan the Q’s asked and answered before they re-ask something that an answer was already provided. I also provide a cross post as r/TheCannalysts encourage our subscribers to benefit from other reddit resources.We are here to learn and share, and we should make the experience as beneficial to subscribers as possible.This is LOOONG and graduate level stuff.https://www.reddit.com/r/weedstocks/comments/6rsk1f/what_ebitda_means_in_the_long_term_for_lps_and/A slow Saturday so I figured I would post this.I admit it. I am fixated…

Continue Reading
Close Menu